

Serial No.: PCT/EP00/01435

Docket No. B45172

46. A peptide as claimed in claim 42 wherein the surface exposed epitope of Cε2 is P4 (SEQ ID NO. 4), or a mimotope thereof.
47. A peptide as claimed in claim 42 wherein the surface exposed epitope of Cε2 is P5 (SEQ ID NO. 5), or mimotope thereof.
48. A peptide as claimed in claim 42 wherein the surface exposed epitope of Cε2 is P6 (SEQ ID NO. 6), or a mimotope thereof.
49. A peptide as claimed in claim 42 wherein the surface exposed epitope of Cε2 is P7 (SEQ ID NO. 7), or a mimotope thereof.
50. A mimotope as claimed in claim 42 wherein the mimotope is a peptide.
51. A peptide as claimed in claim 42 wherein the isolated epitope is derived from a loop structure of the Cε2 domain of IgE.
52. A peptide as claimed in claim 51 wherein the loop structure of the Cε2 domain of IgE is the A-B or the C-D loop.
53. A peptide as claimed in claim 43 wherein the mimotope of P1 is a peptide of the general formula: $h x d h h a n a n x y$;
wherein: h is a hydrophobic amino acid residue; d is an ionic bond donating amino acid residue; a is an acidic amino acid residue; n is an ionically neutral/non-polar amino acid residue; and x is an amino acid.
54. A peptide as claimed in claim 43, wherein the mimotope of P1 is a peptide of the general formula:
Q, X₁, M, D, X₁, X₂, X₃
wherein X₁ is selected from V, I, L, M, F or A; X₂ is selected from D or E; and X₃ is selected from L, I, V, M, A or F.
55. A peptide as claimed in claim 43 wherein the mimotope of P1 is selected from the group consisting of P15q (SEQ ID NO. 11), PT1079 (SEQ ID NO. 13), PT1079GS (SEQ ID NO. 15), PT1078 (SEQ ID NO. 16), and PT15 (SEQ ID NO. 8).
56. A peptide as claimed in claim 44, wherein the mimotope of P2 is P16 (SEQ ID NO. 24).
57. A peptide as claimed in claim 45 wherein the mimotope of P3 is P17 (SEQ ID NO. 26).

0914099-1131-1650

AI CONT

Serial No.: PCT/EP00/01455

Docket No. B45172

58. An immunogen for the treatment of allergy comprising a peptide or a mimotope as claimed in any one of claims 42 to 57, additionally comprising a carrier molecule.
59. An immunogen as claimed in claim 58, wherein the carrier molecule is selected from Protein D or Hepatitis B core antigen.
60. An immunogen for the treatment of allergy comprising a peptide or a mimotope, wherein the immunogen is a chemical conjugate of the peptide or the mimotope as claimed in claims 42 to 57, or wherein the immunogen is expressed as a fusion protein, and a carrier molecule.
61. An immunogen as claimed in claim 58, wherein the peptide or peptide mimotope is presented within the primary sequence of the carrier.
62. An immunogen as claimed in claim 60, wherein the peptide or peptide mimotope is presented within the primary sequence of the carrier.
63. A vaccine for the treatment of allergy comprising an immunogen as claimed in claim 58, further comprising an adjuvant.
64. A vaccine for the treatment of allergy comprising an immunogen as claimed in claim 59, further comprising an adjuvant.
65. A vaccine for the treatment of allergy comprising an immunogen as claimed in claim 60, further comprising an adjuvant.
66. A vaccine for the treatment of allergy comprising an immunogen as claimed in claim 61, further comprising an adjuvant.
67. A vaccine for the treatment of allergy comprising an immunogen as claimed in claim 62, further comprising an adjuvant.
68. A ligand which is capable of recognizing a surface exposed epitope of the Cε2 domain of IgE, characterized in that the ligand is not PTmAb0005.
69. A ligand as claimed in claim 68, wherein the ligand is PTmAb0011 deposited under the Budapest Treaty patent deposit at ECACC on 8th March 1999 under Accession No. 99030805.
70. A pharmaceutical composition comprising a ligand which is capable of recognizing a surface exposed epitope of the Cε2 domain of IgE.
71. A pharmaceutical composition as claimed in claim 70 wherein the ligand is capable of recognizing the C-D Loop of the Cε2 domain of IgE.

TOCT 8841660

A/cont

Serial No.: PCT/EP00/01455

Docket No. B45172

72. A pharmaceutical composition as claimed in claim 71, wherein the ligand is a monoclonal antibody selected from PTmAb0005 or PTmAb0011.
73. A peptide which is recognized by PTmAb0005 or PTmAb0011.
74. An immunogen comprising a peptide as claimed in claim 73.
75. A method of manufacturing a vaccine comprising the manufacture of an immunogen as claimed in claim 58, and formulating the immunogen with an adjuvant.
76. A method of manufacturing a vaccine comprising the manufacture of an immunogen as claimed in claim 60, and formulating the immunogen with an adjuvant.
77. A method for treating a patient suffering from or susceptible to allergy, comprising the administration of a peptide as claimed in any one of claims 42 to 57, to the patient.
78. A method for treating a patient suffering from or susceptible to allergy, comprising the administration of a vaccine as claimed in claim 63 to the patient.
79. A method for treating a patient suffering from or susceptible to allergy, comprising the administration of a vaccine as claimed in claim 64 to the patient.
80. A method for treating a patient suffering from or susceptible to allergy, comprising the administration of a vaccine as claimed in claim 65 to the patient.
81. A method for treating a patient suffering from or susceptible to allergy, comprising the administration of a vaccine as claimed in claim 66 to the patient.
82. A method for treating a patient suffering from or susceptible to allergy, comprising the administration of a vaccine as claimed in claim 67 to the patient.
83. A method of treating a patient suffering from or susceptible to allergy comprising administration of a pharmaceutical composition as claimed in any one of claims 65 to 67, to the patient.

REMARKS

The above-identified application is being entered into the National Phase from PCT application no. PCT/EP00/01455.